Canine deafness.
Strain GM.
Vet Clin North Am Small Anim Pract. 2012 Nov;42(6):1209-24. doi: 10.1016/j.cvsm.2012.08.010. Epub 2012 Oct 10.
Mitochondrial deafness.
Kokotas H, Petersen MB, Willems PJ.
Clin Genet. 2007 May;71(5):379-91. doi: 10.1111/j.1399-0004.2007.00800.x.
miR-182 prevented ototoxic deafness induced by co-administration of kanamycin and furosemide in rats.
Chen J, Liu Z, Yan H, Xing W, Mi W, Wang R, Li W, Chen F, Qiu J, Zha D.
Neurosci Lett. 2020 Apr 1;723:134861. doi: 10.1016/j.neulet.2020.134861. Epub 2020 Feb 24.
Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity.
Sung CYW, Hayase N, Yuen PST, Lee J, Fernandez K, Hu X, Cheng H, Star RA, Warchol ME, Cunningham LL.
Sci Adv. 2024 Jul 26;10(30):eadk9878. doi: 10.1126/sciadv.adk9878. Epub 2024 Jul 24.
Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions.
Tan WJT, Vlajkovic SM.
Int J Mol Sci. 2023 Nov 20;24(22):16545. doi: 10.3390/ijms242216545.
The genetics of deafness.
Nance WE.
Ment Retard Dev Disabil Res Rev. 2003;9(2):109-19. doi: 10.1002/mrdd.10067.
Ototoxic hearing loss from antimalarials: A systematic narrative review.
Dillard LK, Fullerton AM, McMahon CM.
Travel Med Infect Dis. 2021 Sep-Oct;43:102117. doi: 10.1016/j.tmaid.2021.102117. Epub 2021 Jun 12.
Sensorineural Deafness Following Tacrolimus Use.
Lakshmi BS, Vidya B, Reddy MHK, Kumar ACV, Ram R, Kumar VS.
Exp Clin Transplant. 2020 Feb;18(1):110-111. doi: 10.6002/ect.2017.0114. Epub 2018 Jul 2.
[Progress in genetic susceptibility to aminoglycoside-induced deafness].
Tian Y, Chen Z.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021 Apr;35(4):375-379. doi: 10.13201/j.issn.2096-7993.2021.04.021.
Mitochondrial deafness mutations reviewed.
Fischel-Ghodsian N.
Hum Mutat. 1999;13(4):261-70. doi: 10.1002/(SICI)1098-1004(1999)13:4<261::AID-HUMU1>3.0.CO;2-W.
